Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

The list includes Novo Nordisk's blockbuster diabetes injection Ozempic, weight loss shot Wegovy and diabetes pill Rybelsus, ...

A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...

President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...

although there is a good chance they will recover and still deliver strong returns to patient investors. But which one is likely to perform better than the other? Let's find out. Novo Nordisk has ...

At the moment, the hottest GLP-1 treatment is Ozempic. Danish pharmaceutical leader Novo Nordisk (NYSE: NVO) is the brains behind Ozempic, as well as sibling GLP-1 medications including Wegovy ...

Deep-pocketed investors have adopted a bullish approach towards Novo Nordisk NVO, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...

While the recent launches of GLP-1 drugs from Novo Nordisk and Eli Lilly have been ... such as targeting subsets of patient populations or leading with outcomes-related studies, Coyle explained.

Novo Nordisk A/S (NVO) investors were hit by a train as the leading diabetes and obesity drugs maker's recent CagriSema study didn't impress as its performance came in markedly below its ...